Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages 4953-4960

  Sequist, Lecia V ^a   Gettinger, Scott ^a   Senzer, Neil N ^a   Martins, Renato G ^a   Jänne, Pasi A ^a   Lilenbaum, Rogerio ^a   Gray, Jhanelle E ^a   Iafrate, A John ^a   Katayama, Ryohei ^a   Hafeez, Nafeeza ^a   Sweeney, Jennifer ^a   Walker, John R ^a   Fritz, Christian ^a   Ross, Robert W ^a   Grayzel, David ^a   Engelman, Jeffrey A ^a   Borger, Darrell R ^a   Paez, Guillermo ^a   Natale, Ronald ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANAPLASTIC LYMPHOMA KINASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EPIDERMAL GROWTH FACTOR RECEPTOR; RETASPIMYCIN;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; CANCER SIZE; CANCER SURVIVAL; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN TISSUE; INJECTION SITE PAIN; INSOMNIA; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL CHEST PAIN; NAUSEA; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RESPIRATORY DISTRESS; SEPSIS; SIDE EFFECT; TREATMENT RESPONSE; URINE COLOR; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; BENZOQUINONES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79951885125     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.8338     Document Type: Article

References (31)

1. Whitesell L, Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772, 2005 (Pubitemid 41400776)
2. Xu W, Neckers L: Targeting the molecular chaperone heat shock protein 90 provides a multi-faceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13:1625-1629, 2007 (Pubitemid 46952925)
3. Workman P, Burrows F, Neckers L, et al: Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113:202-216, 2007 (Pubitemid 350015011)
4. Nathan DF, Lindquist S: Mutational analysis of Hsp90 function: Interactions with a steroid receptor and a protein kinase. Mol Cell Biol 15:3917-3925, 1995
5. Rutherford SL, Lindquist S: Hsp90 as a capacitor for morphological evolution. Nature 396:336-342, 1998 (Pubitemid 28557387)
6. Grbovic OM, Basso AD, Sawai A, et al: V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A 103:57-62, 2006 (Pubitemid 43076104)
7. Shimamura T, Lowell AM, Engelman JA, et al: Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65:6401-6408, 2005 (Pubitemid 40994428)
8. Suda K, Tomizawa K, Mitsudomi T: Biological and clinical significance of KRAS mutations in lung cancer: An oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29:49-60, 2010
9. Sharma SV, Bell DW, Settleman J, et al: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181, 2007
10. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small- cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253, 2009
11. Mok TS, Wu YL, Thongprasert S, et al: Ge- fitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
12. Maemondo M, Inoue A, Kobayashi K, et al; Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
13. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
14. Kwak EL, Bang Y-J, Camidge R, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (in press)
15. Ge J, Normant E, Porter JR, et al: Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 49:4606-4615, 2006
16. Sydor JR, Normant E, Pien CS, et al: Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 103: 17408-17413, 2006 (Pubitemid 44788982)
17. Sequist LV, Janne PA, Sweeney J, et al: Phase 1/2 trial of the novel Hsp90 Inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982 (Pubitemid 13149996)
20. Demetri GD, LeCesne A, Von Mehren M, et al: Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 22-24, 2010, Orlando, FL
21. Dias-Santagada D, Akhavanfard S, David SS, et al: Rapid targeted mutational analysis of human tumors: A clinical platform to guide personalized cancer medicine. EMB Mol Med 2:146-158, 2010
22. Faber AC, Li D, Song Y, et al: Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106:19503-19508, 2009
23. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284, 1994 (Pubitemid 24107549)
24. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
25. Bonvini P, Gastaldi T, Falini B, et al: Nucleophosmin- anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: Down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 62:1559-1566, 2002 (Pubitemid 34407823)
26. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001 (Pubitemid 32267973)
27. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
28. Shimamura T, Li D, Ji H, et al: Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 68:5827-5838, 2008
29. Sawai A, Chandarlapaty S, Greulich H, et al: Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68:589-596, 2008 (Pubitemid 351380088)
30. Brain J, Slocum K, Cole J, et al: IPI-504, a novel orally administered Hsp90 inhibitor, demonstrates anti-tumor effects in EGFR mutant, kinase inhibitor resistant NSCLC. Annual Meeting of the American Association of Cancer Research, April 14-18, 2007, Los Angeles, CA
31. Horn L, Pao W: EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27:4232-4235, 2009